---
document_datetime: 2025-07-25 16:08:02
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hetronifly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: hetronifly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2411945
conversion_datetime: 2025-12-28 19:11:30.154826
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## HETRONIFLY

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 25/07/2025                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000272312                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z - To update section 2 of the SmPC and section 2 of the package leaflet to include polysorbate 80 as an excipient as per the Excipients Guideline. - To update sections 4.2, 4.4, 4.5, 4.8, 5.2, 5.3 and 6.1 of the SmPC, annex IID, and section 4 of the package leaflet in order to implement changes proposed by member states Spain and Germany as part of the post-opinion linguistic review of the MAA application. - In addition, the MAH has taken the opportunity to update Part B of Annex II to revise the legal status of Hetronifly from \"special and restricted medical prescription\" to \"restricted medical prescription\" in order to align the PI with the RMP.   |            |     | II and PL   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000281029 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted                                                                                                                                                                                                                                                                                                                                                             | 11/07/2025 | N/A |             |

<div style=\"page-break-after: always\"></div>

|                                          | finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation - Accepted   |            |                 |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|
| Variation type IA_IN / EMA/VR/0000266638 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                         | 05/05/2025 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                                                         | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted   |            |            |                        |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000252778 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Henlius Europe GmbH to Accord Healthcare S.L.U.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/02/2025 | 31/03/2025 | SmPC, Labelling and PL |